单剂DSM265(新型疟原虫二氢乳清酸脱氢酶抑制剂)对无并发症恶性疟或间日疟患者的抗疟活性:一项概念验证、开放标签、2a期研究
在秘鲁伊基托斯开展的概念验证开放标签2a期研究,45例无并发症恶性疟或间日疟患者接受单剂口服DSM265。恶性疟400mg组按方案分析14天ACPR为100%(11/11),250mg组为80%(8/10);间日疟主要终点未达成,400mg组0/4、600mg组3/6(50%)、800mg组1/4(25%)获得粗治愈。DSM265耐受良好,恶性疟原虫血症快速清除。
要点
- 恶性疟按方案分析:400mg组14天ACPR 100%(11/11),250mg组80%(8/10)。
- 间日疟主要终点未达成,400mg组粗治愈0/4、600mg组3/6(50%)、800mg组1/4(25%)。
- 最常见不良事件为发热(20/45,44%)和头痛(18/45,40%),无治疗相关严重不良事件。
核心结论
- 单剂DSM265后恶性疟原虫血症快速清除,而对间日疟的清除动力学效果较差。
- DSM265长效作用有潜力在单剂治疗后预防恶性疟复发,应在未来联合研究中进一步评估。
研究设计与样本
- 概念验证、开放标签、2a期研究,在秘鲁伊基托斯Asociación Civil Selva Amazónica开展。
- 纳入18-70岁、体重45-90kg、既往24小时内有发热的临床疟疾(恶性疟或间日疟单一感染)患者。
- 排除有重症疟疾临床或实验室征象、无法口服药物、前14天内使用其他抗疟治疗者。
- 患者分为恶性疟(队列a)和间日疟(队列b),初始队列接受单剂口服DSM265 400mg,随访疗效28天、安全性35天。
- 在初始剂量安全性和疗效评估后,进一步队列接受DSM265剂量递增或递减;主要分析在意向治疗(ITT)和符合方案人群中进行,安全性分析在所有接受研究药物的患者中进行。
主要发现
- 2015年1月12日至2015年12月2日,共连续纳入45例秘鲁患者(恶性疟24例[队列a]、间日疟21例[队列b])。
- 恶性疟符合方案人群:400mg组11/11(100%)和250mg组8/10(80%)在第14天达到ACPR。
- 恶性疟ITT分析:400mg组11/13(85%)和250mg组8/11(73%)在第14天达到ACPR。
- 间日疟符合方案分析:400mg组0/4、600mg组3/6(50%)、800mg组1/4(25%)在第14天达到粗治愈;ITT分析:400mg组0/5、600mg组3/9(33%)、800mg组1/7(14%)达到粗治愈。
- 恶性疟患者28天延长观察期间,4例复发患者中2例观察到编码DSM265靶点DHODH基因的耐药相关突变。
关键数值与推荐
- 恶性疟主要终点为第14天PCR校正的充分临床和寄生虫学应答(ACPR)患者比例,间日疟主要终点为第14天粗治愈患者比例。
- 队列成功(剂量递增标准)定义为队列中至少80%患者达到ACPR(恶性疟)或粗治愈(间日疟)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: DSM265 is a novel, long-duration inhibitor of plasmodium dihydroorotate dehydrogenase (DHODH) with excellent selectivity over human DHODH and activity against blood and liver stages of Plasmodium falciparum. This study aimed to assess the efficacy of DSM265 in patients with P falciparum or Plasmodium vivax malaria infection. METHODS: This proof-of-concept, open-label, phase 2a study was conducted at the Asociación Civil Selva Amazónica in Iquitos, Peru. Patients aged 18-70 years, weighing 45-90 kg, who had clinical malaria (P falciparum or P vivax monoinfection) and fever within the previous 24 h were eligible. Exclusion criteria were clinical or laboratory signs of severe malaria, inability to take oral medicine, and use of other antimalarial treatment in the preceding 14 days. Patients were divided into cohorts of those with P falciparum (cohort a) or P vivax (cohort b) infection. Two initial cohorts received single oral doses of 400 mg DSM265. Patients were followed up for efficacy for 28 days and safety for 35 days. Further cohorts received escalated or de-escalated doses of DSM265, after safety and efficacy assessment of the initial dose. The primary endpoints were the proportion of patients achieving PCR-adjusted adequate clinical and parasitological response (ACPR) by day 14 for patients infected with P falciparum and the proportion of patients achieving a crude cure by day 14 for those infected with P vivax. Cohort success, the criteria for dose escalation, was defined as ACPR (P falciparum) or crude cure (P vivax) in at least 80% of patients in the cohort. The primary analysis was done in the intention-to-treat population (ITT) and the per-protocol population, and safety analyses were done in all patients who received the study drug. This study is registered at ClinicalTrials.gov (NCT02123290). FINDINGS: Between Jan 12, 2015, and Dec 2, 2015, 45 Peruvian patients (24 with P falciparum [cohort a] and 21 with P vivax [cohort b] infection) were sequentially enrolled. For patients with P falciparum malaria in the per-protocol population, all 11 (100%) in the 400 mg group and eight (80%) of ten in the 250 mg group achieved ACPR on day 14. In the ITT analysis, 11 (85%) of 13 in the 400 mg group and eight (73%) of 11 in the 250 mg group achieved ACPR at day 14. For the patients with P vivax malaria, the primary endpoint was not met. In the per-protocol analysis, none of four patients who had 400 mg, three (50%) of six who had 600 mg, and one (25%) of four who had 800 mg DSM265 achieved crude cure at day 14. In the ITT analysis, none of five in the 400 mg group, three (33%) of nine in the 600 mg group, and one (14%) of seven in the 800 mg group achieved crude cure at day 14. During the 28-day extended observation of P falciparum patients, a resistance-associated mutation in the gene encoding the DSM265 target DHODH was observed in two of four recurring patients. DSM265 was well tolerated. The most common adverse events were pyrexia (20 [44%] of 45) and headache (18 [40%] of 45), which are both common symptoms of malaria, and no patients had any treatment-related serious adverse events or adverse events leading to study discontinuation. INTERPRETATION: After a single dose of DSM265, P falciparum parasitaemia was rapidly cleared, whereas against P vivax, DSM265 showed less effective clearance kinetics. Its long duration of action provides the potential to prevent recurrence of P falciparum after treatment with a single dose, which should be further assessed in future combination studies. FUNDING: The Global Health Innovative Technology Fund, the Bill & Melinda Gates Foundation, the National Institutes of Health (R01 AI103058), the Wellcome Trust, and the UK Department of International Development.
引用
- Llanos-Cuentas A, Casapia M, Chuquiyauri R, et al. Antimalarial activity of single-dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in patients with uncomplicated Plasmodium falciparum or Plasmodium vivax malaria infection: a proof-of-concept, open-label, phase 2a study. Lancet Infect Dis. 2018. PMID: 29909069. doi:10.1016/S1473-3099(18)30309-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。